LDETPI: Low Dose Euthyrox in Treatments of Paraquat Intoxication.

Sponsor
Second Affiliated Hospital, School of Medicine, Zhejiang University (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT04132622
Collaborator
First People's Hospital of Hangzhou (Other), Zhejiang Provincial Hospital of TCM (Other)
80
2
48

Study Details

Study Description

Brief Summary

Paraquat is a common human toxicant and accounts for 20 deaths per million persons in the world. Paraquat usually cause multiple organ dysfunction syndrome, including liver, kidney, lung and heart dysfunction. Besides, pituitary insufficiency also occurs on those patients with paraquat poisoning, which leads to multiple endocrine gland dysfunction, involving adrenal gland, thyroid and sex gland.

As a result, the investigators decide to initiate the clinical trial to find whether thyroid replacement therapy can furtherly reduce the mortality, and improve patients long-term prognosis.

Condition or Disease Intervention/Treatment Phase
  • Drug: Levothyroxine Sodium
  • Drug: Traditional therapy
Phase 4

Detailed Description

Paraquat is a common human toxicant and accounts for 20 deaths per million persons in the world. Its accidental or deliberate ingestion is associated with a high mortality rate ranging from 40% to 70%. Paraquat usually cause multiple organ dysfunction syndrome, including liver, kidney, lung and heart dysfunction. Besides, pituitary insufficiency also occurs on those patients with paraquat poisoning, which leads to multiple endocrine gland dysfunction, involving adrenal gland, thyroid and sex gland. Nowadays, steroids, as a hormone replacement therapy, is one of most important drugs for paraquat poisoning, and it has decreased patients' mortality greatly since using it. However, the clinicians have not paid enough attention to thyroid replacement therapy, as thyroid dysfunction is also the key pathophysiological course when paraquat poisoning occurs.

As a result, the investigators decide to initiate the clinical trial to find whether thyroid replacement therapy can furtherly reduce the mortality, and improve patients long-term prognosis.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
80 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Low Dose Euthyrox in Treatments of Paraquat Intoxication: a Randomized, Controlled, Multicenter Trial in China.
Anticipated Study Start Date :
Jan 1, 2020
Anticipated Primary Completion Date :
Dec 31, 2022
Anticipated Study Completion Date :
Dec 31, 2023

Arms and Interventions

Arm Intervention/Treatment
Experimental: Experimental therapy group

Besides Traditional therapy,patients in this group will also receive thyroid replacement therapy.

Drug: Levothyroxine Sodium
Levothyroxine Sodium Tablets (50 ug, calculated by Levothyroxine Sodium ), produced by Merck KGaA, Darmstadt.
Other Names:
  • Euthyrox, H20140052
  • Drug: Traditional therapy
    including steroids, vitamin C, hemodialysis and blood perfusion.
    Other Names:
  • Standard treatment
  • Sham Comparator: Traditional therapy group

    Patients in Standard therapy group will receive treatments according to guideline worldwide.

    Drug: Traditional therapy
    including steroids, vitamin C, hemodialysis and blood perfusion.
    Other Names:
  • Standard treatment
  • Outcome Measures

    Primary Outcome Measures

    1. Rate of death weekly [a week]

      Rate of death in a week.

    2. Rate of death monthly [a month]

      Rate of death in a month.

    3. Rate of death yearly [a year]

      Rate of death in a year.

    4. Survival rate yearly [a year]

      Survival rate in a year.

    Secondary Outcome Measures

    1. Number of Participants with Kidney dysfunction [a week, a month, a year]

      Number of Participants with Kidney dysfunction with paraquat poisoning

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    N/A and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • all the patients who are diagnosed by paraquat poisoning
    Exclusion Criteria:
    • patients who can not cooperate with the trial; patients who would not like to join in the trial.

    Contacts and Locations

    Locations

    No locations specified.

    Sponsors and Collaborators

    • Second Affiliated Hospital, School of Medicine, Zhejiang University
    • First People's Hospital of Hangzhou
    • Zhejiang Provincial Hospital of TCM

    Investigators

    • Study Chair: Yuemei Chen, doctor, Second Affiliated Hospital of Zhejiang University School of Medicine

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    Second Affiliated Hospital, School of Medicine, Zhejiang University
    ClinicalTrials.gov Identifier:
    NCT04132622
    Other Study ID Numbers:
    • CYM2019
    First Posted:
    Oct 21, 2019
    Last Update Posted:
    Oct 22, 2019
    Last Verified:
    Oct 1, 2019
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    Yes
    Studies a U.S. FDA-regulated Device Product:
    No
    Product Manufactured in and Exported from the U.S.:
    Yes
    Keywords provided by Second Affiliated Hospital, School of Medicine, Zhejiang University
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Oct 22, 2019